Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced From the European Union and United States in Healthy Male Participants

NCT06310824 is registered in ClinicalTrials.gov with Xentria, Inc. as lead sponsor.

NCT NCT06310824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06310824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced From the European Union and United States in Healthy Male Participants
Lead sponsor
Xentria, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 5, 2024
Completion date
July 22, 2025
Enrollment
225 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants